Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans).
D000284:Administration, Oral; D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D001842:Bone and Bones / Q000378:metabolism; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D012968:Etidronic Acid / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D005459:Fluorides; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D007554:Isotopes; D008297:Male; D008875:Middle Aged; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D010001:Osteitis Deformans / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism / Q000652:urine; D010146:Pain / Q000188:drug therapy; D010919:Placebos; D011859:Radiography; D013325:Strontium Isotopes; D013997:Time Factors
D007554:Isotopes; D009943:Organophosphorus Compounds; D010919:Placebos; D013325:Strontium Isotopes; D000469:Alkaline Phosphatase; D012968:Etidronic Acid; D005459:Fluorides; D006909:Hydroxyproline